Get the Daily Brief
Latest Biotech News
Regeneron Steps Back as Anne Wojcicki Wins 23andMe Bankruptcy Bid
Regeneron Pharmaceuticals has lost the bankruptcy auction for 23andMe to former CEO Anne Wojcicki, whose nonprofit TTAM Research Institute submitted a $305 million bid exceeding Regeneron's $256...
Roche and Prothena Push Prasinezumab to Phase III Despite Mixed Phase IIb Results
Despite falling short in mid-stage trials, Roche and Prothena are advancing prasinezumab, a Parkinson’s disease monoclonal antibody, into Phase III testing. Analysts remain cautious, assigning a...
Nanoneedle Patch Developed at King’s College Offers Painless Alternative to Biopsies
Researchers at King's College London have created a nanoneedle patch equipped with millions of microscopic silicon needles thousands of times thinner than human hair, designed to collect molecular...
NextCure Invests $745M in Simcere’s Early-Stage ADC to Expand Oncology Pipeline
NextCure has inked a $745 million deal to secure ex-Greater China rights to Simcere Zaiming’s phase 1-stage antibody-drug conjugate (ADC) SIM0505, targeting CDH6. The ADC combines a targeted...
FDA Faces Delays and Resource Constraints Impacting Drug Approvals
The FDA is experiencing delays and potential consolidations within operational units such as human resources and communications to address workload challenges. Significant delays in drug...
Proteogenomics Tool ‘moPepGen’ Unveils Hidden Genetic Mutations at Protein Level
Scientists from UCLA and the University of Toronto have developed moPepGen, an innovative algorithm that enhances the detection of complex protein variants stemming from diverse genetic...
Sarepta Suspends Duchenne Gene Therapy Shipments Following Second Patient Death
Sarepta Therapeutics has temporarily halted Elevidys shipments for non-ambulatory Duchenne muscular dystrophy patients after a second death due to acute liver failure. Both fatalities involved...
Metabolic Drug DD01 Shows Promise in Reducing Liver Fat and Weight in MASH Patients
D&D Pharmatech reported positive phase 2 results for DD01, a dual GLP-1/glucagon receptor agonist, demonstrating significant reductions in liver fat—over 30% in 75.8% of treated patients—and...
Global warming worsens obstructive sleep apnea burden
New research published in Nature Communications reveals that rising global temperatures could increase the prevalence and severity of obstructive sleep apnea (OSA), a common yet underdiagnosed...
Nanoneedle patches promise pain-free cancer diagnostics
Scientists at King’s College London have unveiled a nanoneedle patch containing tens of millions of microscopic needles capable of sampling molecular data from tissues without pain or damage. This...
Massachusetts Governor Healey boosts biotech workforce with $1B investment
Massachusetts Governor Maura Healey has secured recognition as BIO’s 2025 Governor of the Year for spearheading a $1 billion state investment in life sciences through the Mass Leads Act. The...
Gilead and Arcellx report safer multiple myeloma CAR-T therapy
Gilead and Arcellx presented updated data indicating their cell therapy anito-cel for multiple myeloma maintains a favorable safety profile compared to competitors, while delivering comparable...
New hereditary syndrome impairs DNA repair, raises cancer risks
Researchers from the University of Birmingham and Cancer Research UK have identified DIAL syndrome, a novel hereditary disorder caused by DIAPH1 gene mutations that compromise DNA double-strand...
AI-powered dataset tracks mammal interactions in the Swiss Alps
The EPFL research team introduced MammAlps, a comprehensive, multi-view dataset capturing wild mammal behaviors in their natural Swiss Alps habitat. This resource, integrating video and sensor...
Psilocybin trial shows lasting relief for cancer-related depression
A phase 2 open-label study published in the American Cancer Society’s journal CANCER demonstrates that a single 25 mg dose of psilocybin, combined with psychological support, produces sustained...
Sarepta suspends Duchenne gene therapy shipments after second liver failure death
Sarepta Therapeutics halted shipments of its FDA-approved Duchenne muscular dystrophy gene therapy Elevidys to non-ambulatory patients following a second fatal case of acute liver failure. Both...
T cell blood test offers new route for celiac disease diagnosis
Novoviah Pharmaceuticals developed the Novoleukin test platform, a 24-hour whole blood assay measuring gluten-specific T cell reactivity via interleukin-2 release to aid celiac disease diagnosis...
Magnetic soft millirobot achieves locomotion and sensing integration
Researchers led by W. Zeng, X. Ding, and Y. Jin unveiled a flexible millirobot using magnetic nanoparticles embedded in a polymer matrix capable of simultaneous movement and environmental sensing....
Massachusetts Commits $1 Billion to Life Sciences Workforce Development
Massachusetts Governor Maura Healey has secured a $1 billion commitment through the Mass Leads Act to bolster the state's life sciences ecosystem, emphasizing workforce development. This...
Sarepta Suspends Duchenne Gene Therapy After Second Liver Failure Death
Sarepta Therapeutics has paused shipments of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys for non-ambulatory patients following a second death attributed to acute liver failure....